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Abstract
Despite progress in the treatment of acute myelogenous leukaemia (AML) the outcome often remains poor. Tumour necrosis factor
related apoptosis-inducing ligand (TRAIL) is a promising therapeutic agent in many different types of tumours, but AML cells are relatively
insensitive to TRAIL-induced apoptosis. Here we show that TRAIL-induced apoptosis in AML cells is predominantly mediated by death
receptor 4 (DR4) and not DR5. Therefore, we constructed a variant of TRAIL (rhTRAIL-C3) that is a strong inducer of DR4-mediated
apoptosis. TRAIL-C3 demonstrated much stronger pro-apoptotic activity than wild-type (WT) TRAIL in a panel of AML cell lines as well
as in primary AML blasts. The higher pro-apoptotic potential was further enhanced when the TRAIL mutant was used in combination
with BMS-345541, a selective inhibitor of inhibitor-B kinases. It illustrates that combination of this TRAIL variant with chemotherapeutics
or other targeted agents can kill AML with high efficacy. This may represent a major advantage over the currently used therapies that
have serious toxic side effects. The high efficacy of rhTRAIL-C3 containing therapies may enable the use of lower drug doses to reduce
the toxic side effects and improve patient outcome. Our findings suggest that the rational design of TRAIL variants that target DR4
potentiate the death-inducing activity of TRAIL and offer a novel therapeutic strategy for the treatment of AML.
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Introduction
Acute myeloid leukaemia (AML) is a heterogeneous group of
diseases characterized by uncontrolled proliferation of clonal neo-
plastic haematopoietic precursor cells and impaired production of
normal haematopoiesis leading to neutropenia, anaemia and
thrombocytopenia [1]. The 5 year survival rate of AML patients has
remained at 20–30% since the 1970s [2]. The outcome for AML
patients depends on a variety of factors, including the age of the
patient, the intensity of post-remission therapy and the biological
characteristics of the disease [3–5]. Thus there remains a need for
rational, minimally toxic but effective therapies for AML [6].
Tumour necrosis factor related apoptosis-inducing ligand
(TRAIL) is a promiscuous cytokine with the ability to bind to five
different receptors. TRAIL-R1 death receptor (DR)4 and TRAIL-R2
(DR5), the two apoptosis-inducing TRAIL receptors, contain a
conserved cytoplasmic death domain motif that undergoes a con-
formational change upon binding of TRAIL and results in the
recruitment of the adaptor molecule Fas-associated via death
domain (FADD) [7–9]. This facilitates caspase-8 recruitment and
activation, which activates the apoptotic machinery. Decoy recep-
tor 1 (DcR1/TRAIL-R3), decoy receptor 2 (DcR2/TRAIL-R4) and
the soluble receptor osteoprotegerin lack or have a truncated
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cytoplasmic death domain and thus these receptors act to prevent
apoptosis by sequestering available TRAIL or by interfering with
the formation of a DR4 or DR5 signalling complex [10, 11].
A number of haematological malignancies are sensitive to
TRAIL either as a single agent or in combination with chemother-
apeutics [12–14]. Chronic lymphocytic leukaemia (CLL) cells
undergo TRAIL-induced apoptosis by activation of DR4 rather
than DR5 [15], contrasting with the suggestion that DR5 may con-
tribute more than DR4 to TRAIL-induced apoptosis in cancer cells
expressing both TRAIL receptors [16]. Furthermore, primary man-
tle cell lymphoma cells were also found to be sensitive to TRAIL
and similar to CLL cells, the TRAIL-death signal was almost exclu-
sively transmitted through DR4 [12]. Interestingly, a study of 72
primary AML blasts revealed that while many AML blasts
expressed DR4 (48.6%) and DR5 (12.5%), the AML cells gener-
ally showed low sensitivity to TRAIL [17].
A number of mechanisms have been associated with TRAIL
resistance in AML. It has been suggested that high levels of decoy
receptors were associated with TRAIL insensitivity [17].
Overexpression of cellular FADD-like Interleukin-1 converting
enzyme (ICE)-like inhibitory protein (c-FLIP) has been reported 
as another mechanism of resistance of AML cells to TRAIL [18].
High c-FLIP expression has also been recently reported to be
linked to inferior outcome in AML patients with normal karyotype
and intermediate risk [19]. Therefore based on these observa-
tions, we suggested that by increasing the affinity of TRAIL for
DR4 a higher efficacy may be achieved, thus making engineered
TRAIL suitable for the treatment of AML and other haematological
malignancies.
Experimental procedures
Site-directed mutagenesis, expression 
and purification of rhTRAIL variants
Construction and purification of wild-type (WT) TRAIL and vari-
ants was performed as described before [20]. The amino acid
alterations in rhTRAIL-C3 did not change the homotrimeric struc-
ture of the molecule as the gel filtration elution profile of the
mutant was not different from that of WT rhTRAIL (Fig. S2).
Determination of receptor binding by surface
plasmon resonance (SPR)
Binding experiments were performed with a SPR-based biosensor
Biacore 3000 (GE Healthcare, Munich, Germany). Research grade
CM5 sensor chips, N-hydroxysuccimide, N-ethyl-N-(3-diethy-
laminopropyl) carbodiimide, ethanolamine-HCl and standard
buffers, e.g. HBS-N and HBS-EP were purchased from the manu-
facturer. All the buffers were filtered and degassed. Immobilization
of DR4-Ig and DR5-Ig receptors (R&D Systems, Minneapolis, MN,
USA) on the sensor surface of a Biacore CM5 sensor chip was per-
formed following a standard amine coupling procedure according
to the manufacturer’s instructions. Receptors were coated at a
level of 600–1000 response units (RU). Reference surfaces con-
sisted of activated CM dextran, subsequently blocked with
ethanolamine. 50 l aliquots of WT rhTRAIL or variants were
injected in 3-fold at concentrations ranging from 0.5 to 250 nM 
at 70 l/ml and at 37C using HBS-N supplemented with 0.005%
surfactant P20 (Biacore, Uppsala, Sweden) as running and sample
buffer. Binding of ligands to the receptors was monitored in real
time. Pre-steady state data was obtained by recording the
responses 30 sec. after the end of injections for all concentrations.
The response data as a function of TRAIL concentration were fit-
ted by using a four-parameter equation to give apparent affinity
constants. Between injections, the receptor/sensor surface was
regenerated using 1:1 (10 mM glycine 1.5 M NaCl pH 2 : ethylene
glycol) and a contact time of 35 sec.
Determination of receptor binding 
by competitive ELISA
Nunc Maxisorb plates were coated for 2 hrs with DR4-Ig 
(100 ng/well) in 0.1 M sodium carbonate/bicarbonate buffer 
(pH 8.6) remaining binding sites were subsequently blocked 
with 2% bovine serum albumin (BSA) for 1 hr. Serial dilutions of
soluble recombinant receptor proteins DR4, DR5, DcR1 and DcR2 
(Ig fusion proteins, 0–500 ng/well) were pre-incubated with WT
rhTRAIL or rhTRAIL-C3 (10 ng/well) in phosphate-buffered saline
(PBS; pH 7.4) for 1 hr at room temperature, added to the wells and
incubated for an additional 1 hr. After washing for six times with
Tris-buffered saline with Tween (TBST), a 1:200 dilution of anti-
TRAIL antibody (R&D Systems) was added and incubated for 1 hr
at room temperature, and, after washing six times with TBST, 
subsequently incubated with a 1:25,000 dilution of a horseradish
peroxidase-conjugated swine–anti-goat antibody (BioSource
International, Invitrogen, Carlsbad, CA, USA). After washing six
times with TBST, 100 l of 1-step Turbo TMB solution (Pierce,
Thermo Fisher Scientific, Rockford, IL, USA) was added for 
20 min., the reaction was stopped with 100 l 1 M sulphuric acid.
The absorbance was measured at 450 nM on a microplate reader
(Thermo Fisher Scientific, Rockford, IL, USA). Binding of WT
rhTRAIL or rhTRAIL-C3 to immobilized DR4-Ig with 0 ng/well of
the soluble receptors was taken as 100%, and binding at other
concentrations of soluble receptors was calculated relative to 
0 ng/well of soluble receptor.
Cell lines and treatment
NHEK primary normal human epidermal keratinocytes (NHEK,
PromoCell, Heidelberg, Germany) were maintained in serum free
keratinocyte growth medium (PromoCell, C-12003), supplemented
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with bovine pituitary extract (0.004 ml/ml), epidermal growth fac-
tor (0.125 ng/ml), insulin (5 g/ml), hydrocortisone (0.33 g/ml),
epinephrine (0.39 g/ml), holo-transferrin (10 g/ml) and CaCl2
(0.06 mM) (all from PromoCell). Primary human dermal fibrob-
lasts (a kind gift from Dr. Linda Howard, REMEDI, National
University of Ireland, always) were cultured in low glucose 
(100 mg/l) Dulbecco’s modified Eagle’s medium (Sigma-Aldrich, 
St. Louis, MO, USA) supplemented with 10% foetal bovine serum
(FBS), 50 U/ml penicillin and 50 g/ml streptomycin.
Keratinocytes and fibroblasts were seeded at a density of 50,000
cells/ml, 2 days before treatment. HL60 [German Collection of
Microorganisms and Cell Cultures (DSMZ), ACC 3], EM-2 (DSMZ,
ACC 135) and A2780 cells were maintained in RPMI medium sup-
plemented with 10% FBS , 2 mM glutamine, 50 U/ml penicillin and
50 mg/ml streptomycin. HL60, EM-2 and A2780 cells were seeded
at 5  105, 3  105 and 3.5  105 cells/ml, respectively, 24 hrs
prior to treatment. The ML-1 cell line was maintained in RPMI
medium supplemented with 20% FBS, 2 mM glutamine, 50 U/ml
penicillin and 50 mg/ml streptomycin and seeded at 3  105
cells/ml 24 hrs prior to treatment. MOLM-13 cells (DSMZ, ACC
554) were maintained in RPMI medium supplemented with 10%
FBS, 2 mM glutamine, 1 mM sodium pyruvate, 1% non-essential
amino acids (NEA), 50 U/ml penicillin and 50 mg/ml streptomycin
and seeded at 1  106 cells/ml 24 hrs prior to treatment. OCI-
AML3 cells (DSMZ, ACC 582) were maintained in Modified Eagle
Medium (MEM) supplemented with 20% FBS, 2 mM glutamine, 1
mM sodium pyruvate, 1% NEA, 50 U penicillin and 50 mg/ml
streptomycin and seeded at 7.5  105 cells/ml 24 hrs prior to
treatment. All cells were cultured at 37C with 5% CO2 in a 
humidified incubator. All reagents were from Sigma-Aldrich unless
otherwise stated. To examine the pro-apoptotic potential of the
DR4-selective TRAIL variants, as a measure of their receptor
selectivity and/or biological activity, cells were treated with
increasing concentrations (0–250 ng/ml) of rhTRAILN199R/K201H,
rhTRAILG131R/N199R/K201H (rhTRAIL-C3), rhTRAILD269H/E195R or
rhTRAIL-WT.
Isolation and culture of primary AML blasts:
BM MNCs were isolated by density gradient centrifugation and
cryopreserved in 10% dimethyl sulphoxide (DMSO) freezing
medium. Following a rapid thawing and centrifugation to remove
DMSO of the freezing medium, cells were cultured in RPMI
containing 10% FBS, 2 mM glutamine, 1 mM sodium pyruvate, 
50 U/ml penicillin and 50 mg/ml streptomycin and seeded at 1 
106 cells/ml. Cell viability was assessed at the time of thawing the
cells and experiments were only carried out in samples that
showed at least 75% viability. In addition, samples that showed
high rate of spontaneous death and the percentage of live cells
reduced to 25% or less at time of harvesting were also excluded
from further analysis. The cells were treated with 250 ng/ml of WT
rhTRAIL or rhTRAIL-C3 alone for 24 hrs or in combination with 
5 M BMS-345541 added simultaneously.
Annexin V staining
Externalization of phosphatidyl serine on the plasma membrane
of apoptotic cells was detected using annexin V-fluoro isothio-
cyanate (FITC) (IQ Corporation, Groningen, The Netherlands) as
previously described [21].
Determination of surface TRAIL 
receptor expression
Cells were removed from culture dishes, harvested by centrifuga-
tion and washed twice with 1% BSA in PBS. Cells were incubated
with 1:100 dilution of primary antibodies (DR4 and DR5: neutral-
izing mouse monoclonal antibodies, Alexis, DcR1 and DcR2: neu-
tralizing goat polyclonal antibodies, R&D Systems) in 1% BSA in
PBS for 40 min. on ice. After two washes in 1% BSA/PBS, cells
were resuspended in 1:50 dilution of FITC-labelled secondary anti-
body and incubated for 40 min. on ice. Excess secondary antibody
was removed by washing first in 1% BSA in PBS and then PBS.
Cells were fixed in 1% formaldehyde/PBS before analysis by flow
cytometry (FacsCalibur, Becton Dickinson, Franklin Lakes, NJ,
USA).
Western blotting
Polyacrylamide gel electrophoresis and Western blotting was car-
ried out as previously described [22]. For antigen detection mem-
branes were incubated with antibodies to actin (1:500; Sigma),
caspase-3 and -8 (1:1000; Cell Signaling Technology, Danvers,
MA, USA) overnight at 4C followed by 2 hrs incubation at room
temperature with secondary antibodies (1:5000; Pierce). Protein
bands were visualized using Supersignal Ultra Chemiluminescent
Substrate (Pierce) on X-ray film (Agfa, Mortsel, Belgium).
Crosslinking of agonistic anti-DR4 
and -DR5 antibodies
Agonistic DR4 and DR5 antibodies (200 nM; Novartis, Basel,
Switzerland) were incubated with goat anti-human Fc antibody
(crosslinking antibody, 600 nM; Jackson ImmunoResearch
Laboratories, West Grove, PA, USA) in serum free cell culture
media for 30 min. at room temperature then added to the cell cul-
ture for 24 hrs.
7-aminoactinomycin D staining
Following treatment, cells were removed from culture dishes, har-
vested by centrifugation and washed with PBS. To fix, cells were
resuspended in 70% ethanol and incubated overnight at 4C. Cells
were recovered by centrifugation, resuspended in PBS containing
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0.3 g/ml 7-aminoactinomycin D (7-AAD) and incubated for 10
min. at room temperature in the dark. Cells were immediately ana-
lyzed by flow cytometry (FacsCalibur, Beckton Dickinson).
Measurement of mitochondrial transmembrane
potential (	m)
	m was measured using the fluorescent dye tetramethylrho-
damine ethyl ester perchlorate (TMRE). Cells (500 l) were trans-
ferred from wells to fluorescence-assisted cell sorter (FACS)
tubes and TMRE was added to a final concentration of 100 nM.
Cells were incubated for 30 min. at room temperature in the dark
followed by immediate analysis by flow cytometry (FacsCalibur
flow cytometer, Beckton Dickinson). As a positive control for
mitochondrial depolarization, cells were treated for 2 hrs with 
10 M carbonyl cyanide 3-chlorophenylhydrazone.
Results
Design and biochemical characterization 
of rhTRAIL-C3
Although approximately 50% of AMLs express at least one death-
inducing TRAIL receptor on the cell surface, AML blasts display a
low sensitivity to TRAIL [17]. In AML blasts, TRAIL fails to activate
pro-caspase-8, indicating that inadequate receptor activation by
TRAIL may be the cause of the low sensitivity [17]. Since DR4 is
more frequently expressed on AML blasts than DR5, it was
suggested that a high affinity, DR4-selective TRAIL variant would
be able to trigger AML cell apoptosis.
In the search for an rhTRAIL variant that can efficiently induce
apoptosis in AML blasts, we have combined mutation D218H
(replacement of the aspartate at position 218 to histidine) with
mutation G131R (glycine at position 131 to arginine) that, respec-
tively, reduces the affinity of TRAIL to DR5 [23] or increases the
apoptotic potential of rhTRAIL (Reis et al.). However, combination
of G131R with D218H did not result in higher biological activity
compared to WT rhTRAIL (Fig. S1). Scanning the receptor binding
interface of TRAIL with the protein design algorithm FoldX [24,
25] identified additional mutations which potentially improved
DR4 selectivity. A N199R/K201H double mutation (replacement of
the asparagine at position 199 to arginine and the lysine at posi-
tion 201 to histidine) was predicted to improve DR4 binding
(Predicted Ginteraction – 0.44 kcal/mol) and combination of
these mutations with the G131R mutation was feasible from a
structural point of view. Moreover, the combined effect of these
mutations was predicted to minimally affect DR5 binding
(Predicted Ginteraction 
 0.1 kcal/mol). The TRAIL
G131R/N199R/K201H mutant (rhTRAIL-C3) was constructed by
site directed mutagenesis and purified as a trimeric protein as
described previously [26]. The retained homotrimeric structure of
rhTRAIL-C3 was confirmed by the unchanged gel filtration elution
profile in comparison to WT rhTRAIL (Fig. S2).
Receptor binding of rhTRAIL-C3 to DR4 and DR5 was
assessed in real time with SPR (Fig. S3) and apparent dissociation
constants (KD) were calculated from pre-steady state response
values (Fig. S4). rhTRAIL-C3 showed a 3-fold increase in apparent
affinity for DR4-Ig (Table 1) and a very modest reduction in affin-
ity to DR5-Ig when compared to WT rhTRAIL (Table 1, Fig. S3).
Intriguingly, when looking at the sensograms for DR5-Ig binding
of WT rhTRAIL and rhTRAIL-C3, an initial off-rate has been
observed at high concentrations of rhTRAIL-C3 (Fig. S3D). This
initial off-rate seems to represent the dissociation of trimeric
rhTRAIL-C3 from one or two receptor molecules, suggesting a
lower affinity of rhTRAIL-C3 towards DR5 than of WT rhTRAIL.
However, this difference in the affinity could not be reflected in the
pre-steady state affinity determination.
To determine the receptor preference of rhTRAIL-C3 when
multiple TRAIL receptors are present, competitive ELISA assays
were performed. Plates were coated with DR4-Ig. Soluble 
DR4-, DR5-, DcR1- or DcR2-Ig were pre-incubated as competitors
with WT rhTRAIL or rhTRAIL-C3 for 30 min. and added to the
DR4-coated wells. Binding of WT rhTRAIL or rhTRAIL-C3 to
immobilized DR4-Ig was measured. rhTRAIL-C3 showed a 7-fold
reduction in binding to immobilized DR4-Ig in the presence of sol-
uble DR4-Ig when compared to WT rhTRAIL (Table 1, Fig. S4C),
indicating a significant increase in affinity for DR4. In contrast, WT
rhTRAIL and rhTRAIL-C3 showed similar behaviour when soluble
DR5-Ig or DcR2-Ig was the competitor (Table 1, Fig. S4D and F).
DcR1-Ig also reduced binding of rhTRAIL-C3 to immobilized DR4-
Ig by 3.5-fold when compared to WT rhTRAIL (Table 1, Fig. S4E).
In summary, rhTRAIL-C3 has a higher affinity for DR4 and a mod-
erate increase in affinity for DcR1. The binding preference of the
variant to DR5 and DcR2 remained unchanged.
Table 1 SPR measurements of DR4 and DR5 binding affinities and
competitive ELISA for DR4 and DR5, and decoy receptors, DcR1 and
DcR2. Apparent KA and EC50 ratios were calculated relative to WT
rhTRAIL.
Apparent KA ratio rhTRAIL-C3 / WT rhTRAIL by SPR
DR4 DR5
2.7  0.1 0.83  0.07
EC50 ratio rhTRAIL-C3/WT rhTRAIL binding to DR4-Ig 
by competitive ELISA
DR4-Ig competition DR5-Ig competition
7.1  0.3 1.1  0.3
DcR1-Ig competition DcR2-Ig competition
3.5  0.6 1.1  0.2
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rhTRAIL-C3 has a DR4-selective, agonistic activity
Receptor selectivity and receptor activating ability (agonistic activ-
ity) of rhTRAIL-C3 was initially tested on tumour cells which
responded exclusively to either DR4- or DR5-activation (EM-2
chronic myeloid leukaemia cells and A2780 ovarian carcinoma
cells, respectively) [23]. The two cell types were treated with 
WT rhTRAIL, rhTRAIL-C3 or D269H/E195R, a DR5-selective
TRAIL variant [20]. Induction of apoptosis was measured by
annexin V assay. As reflected by the ED50 values, D269H/E195R
demonstrated very weak apoptosis-inducing activity in EM-2 cells,
but appeared to be the strongest inducer of apoptosis of the three
rhTRAIL variants in A2780 cells, indicative of the DR4- or DR5
sensitivity of the two cell lines, respectively (Fig. 1). Conversely,
the rhTRAIL-C3 variant displayed the highest pro-apoptotic activ-
ity in the DR4-responsive cell line, EM-2 (ED50  3.78 ng/ml for
rhTRAIL-C3 versus 17.53 ng/ml for WT rhTRAIL), and only
marginal activity in the DR5-responsive A2780 cells (5.65, 121.7
and 1972.3 ng/ml ED50 values for D269H/E195R, WT rhTRAIL 
and rhTRAIL-C3, respectively, Fig. 1A). These results indicate 
that rhTRAIL-C3 is an agonistic TRAIL variant that preferentially
activates DR4.
Similar testing was carried out with the double mutant
N199R/K201H, with predicted increased DR4-selectivity.
N199R/K201H induced apoptosis in the DR4-responsive ML-1
(Fig. S1A) and EM-2 (Fig. S1B) cells, but not A2780 cells 
(Fig. S1C) confirming that the mutations increase DR4-selectivity.
The DR4-mediated action of rhTRAIL-C3 was further assessed
in BJAB cells overexpressing DR4 or DR5 variants lacking the 
C-terminal tail involved in FADD binding (CT-DR4-BJAB, CT-
DR5-BJAB). These DR4 and DR5 mutant receptors are not func-
tional and likely to act in a dominant negative fashion by interfer-
ing with proper DISC formation on trimerized receptors [27].
rhTRAIL-C3 triggered apoptosis more efficiently than WT
rhTRAIL in WT-BJAB cells, GFP overexpressing BJAB cells and
CT-DR5-BJAB cells (Fig. 2A, B and D). However, rhTRAIL-C3
failed to kill CT-DR4-BJAB cells, confirming its DR4-selective
pro-apoptotic action (Fig. 2C). This was reflected in the ED50 val-
ues, as it stayed nearly unchanged in WT, GFP and CT-DR5
cells, but increased by 13.49-fold in the CT-DR4 cells (Fig. 2).
WT-rhTRAIL on the other hand showed a 2.94-fold increase in the
ED50 value on CT-DR5 BJAB cells and a 10.38-fold increase on
the CT-DR4 cells, indicating its dual specificity towards DR4
and DR5 (Fig. 2).
rhTRAIL-C3 is a potent inducer 
of apoptosis in AML
The ability of rhTRAIL-C3 to induce AML cell death was assessed
in ML-1, MOLM-13, OCI-AML3 and HL-60 AML cell lines.
According to the French–American–British (FAB) classification,
HL-60 cells are type M3 acute promyelocytic leukaemia cells, 
ML-1 and OCI-AML3 are M4 AMLs and MOLM-13 is type M5a
[28–31]. All four cell lines express both DR4 and DR5 on their
surface (Fig. 3).
Cells were treated with 10–250 ng/ml of WT rhTRAIL, rhTRAIL-
C3 or D269H/E195R (DR5-selective TRAIL variant) for 24 hrs and
induction of apoptosis was quantified with annexin V staining.
rhTRAIL-C3 appeared to be a much more potent apoptosis-
inducer than WT rhTRAIL in HL-60, ML-1 and MOLM13 cells 
(Fig. 4). Like WT rhTRAIL, rhTRAIL-C3 could not induce apopto-
sis in OCI-AML3 cells (Fig. 4D). OCI-AML3 cells are completely
resistant to TRAIL (Fig. 4) probably due to high expression of 
X-linked inhibitor of apoptosis protein (XIAP), Bcl-XL and Mcl-1
Fig. 1. DR4-selectivity of rhTRAIL-C3. DR4-responsive EM-2 chronic
myelogenous leukaemia cells (A) and DR5-responsive A2780 ovarian car-
cinoma cells (B) were treated with increasing doses of rhTRAIL-C3
(G131R/N199R/K201H), WT rhTRAIL or DR5-selective rhTRAIL variant
(D269H/E195R) for 24 hrs. Induction of apoptosis was determined using
annexin V assay. The graphs show the percentage of dead cells  S.E.M.
determined with flow cytometric analysis of annexin V positivity in three
independent experiments.
J. Cell. Mol. Med. Vol 15, No 10, 2011
2221© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
(data not shown). On the other hand, the DR5-selective TRAIL
variant was a very weak inducer of apoptosis in all four cell lines.
This is despite the fact that D269H/E195R is substantially more
potent than WT rhTRAIL in DR5-responsive cell lines, such as
A2780 or the colon carcinoma cell line Colo205 [20, 32].
We have previously reported that in ML-1 cells only DR4 is
functional [20]. The functionality of DR4 and DR5 in HL-60, ML-
1, MOLM-13, OCI-AML3 and EM-2 cells was determined using
agonistic anti-DR4 and anti-DR5 antibodies (Novartis). The cells
were treated with 5–20 nM of the agonistic antibodies with or
without previous crosslinking of the antibodies through their Fc
region using a secondary antibody. After 24 hrs of treatment,
induction of apoptosis was determined with 7-AAD staining.
Results demonstrated that in HL-60, ML-1 and EM-2 cells DR4
Fig. 2. Deficiency of DR4 blocks rhTRAIL-C3 induced apoptosis. WT BJAB cells (A), BJAB cells overexpressing GFP (B), non-functional, C-terminal dele-
tion mutants of DR4 (C) or DR5 (D) were treated with WT rhTRAIL and rhTRAIL-C3. Induction of apoptosis was determined by measuring loss of mito-
chondrial membrane potential (	m).
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was the primary mediator of TRAIL-induced apoptosis (Fig. 5A, B
and E), in OCI-AML3 cells signalling through DR4 and DR5 was
blocked and in MOLM-13 cells, while both receptors were func-
tional, DR5 required activation using a tetravalent, crosslinked
antibody (Fig. 5C and D).
To examine whether the high affinity of rhTRAIL-C3 enhanced
DR4 activation, HL-60 cells, which have defective DR5 signalling,
were selected. Two apical events of DR activation, i.e. pro-
caspase-8 activation and NF-B activation were monitored 
over time as a measure of DR4 activation. Cells were treated with
100 ng/ml of WT rhTRAIL or rhTRAIL-C3 for 5–120 min. Cells
were then harvested for detection of pro-caspase-8 processing
into its active fragments, phosphorylation and degradation of
IB. To examine the kinetics of apoptosis induction, as another
measure or receptor activation, at the end of the incubation time
the unbound ligands were removed from the cells by a wash step
and the cells were resuspended in normal growth medium. The
cells were then further incubated in total for 12 hrs to allow the
execution of the apoptotic programme. As a positive control,
ligands were left on the cells for 12 hrs.
rhTRAIL-C3 induced earlier and stronger processing of pro-
caspase-8 than WT rhTRAIL, indicating faster and more efficient
DR4 activation by the TRAIL variant (Fig. 6A). The stronger and
faster DR4 activation by rhTRAIL-C3 was also reflected by the pat-
tern of IB phosphorylation and resulting degradation (Fig. 6B).
The faster and more robust receptor activation induced by
rhTRAIL-C3 was finally mirrored in the level and kinetics of apop-
tosis induction (Fig. 6C). rhTRAIL-C3 did not only induce higher
level of cell death than WT rhTRAIL (67% and 53%, respectively,
for full dosage please refer to Fig. 4), but it also required only 
14 min. to reach its half-maximal effect, while WT rhTRAIL
required 73 min. for the same (Fig. 6C).
Fig. 3. Cell surface expression of TRAIL receptors in OCI-AML3, HL-60 and MOLM-13 cells. Cell surface expression of DR4, DR5, DcR1 and DcR2 was
measured by immunostaining and detected with flow cytometry (FacsCanto II, Beckton Dickinson). The histograms are representatives of three independ-
ent experiments. Red filled peaks: isotype control, green open peaks: TRAIL receptor stained sample.
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rhTRAIL-C3 is a potent inducer of apoptosis 
in primary AML blasts
To test whether rhTRAIL-C3 is a more potent apoptosis inducer
than WT rhTRAIL in AML, primary AML blasts were analyzed for
TRAIL receptor expression and sensitivity to WT rhTRAIL or
rhTRAIL-C3, alone or in combination with the inhibitor B kinase
(IKK) inhibitor, BMS-345541. NF-B has been shown to regulate
the expression of a number of anti-apoptotic genes, including cel-
lular FADD-like Interleukin-1 converting enzyme (FLICE)-inhibitory
protein (c-FLIP) and XIAP, two molecules that have been associ-
ated with TRAIL resistance of AML and other tumour types [18,
33]. Accordingly, inhibition of NF-B have been shown to restore
TRAIL sensitivity in a range of tumour types [34, 35]. Further sup-
porting the viability of the combination of an NF-B inhibitor and
TRAIL, we have found that HL-60 cells can be greatly sensitized to
TRAIL by simultaneous inhibition of NF-B activation (Fig. S5).
Most samples expressed the TRAIL receptor at a detectable
level, and many displayed a high level of decoy receptor (Table 2)
expression. The clinical information of the analyzed samples is
summarized in Table 3. As expected, the AML samples had gener-
ally low TRAIL sensitivity (Fig. 7A). However, analysis of the
samples that showed some level of TRAIL sensitivity revealed that
rhTRAIL-C3 had a significantly higher pro-apoptotic activity than
WT rhTRAIL (Fig. 7A, P  0.009; paired Student’s t-test).
The effect of BMS-345541 on WT rhTRAIL/rhTRAIL-C3
sensitivity was tested in 6 AML samples, including both rhTRAIL
Fig. 4. Pro-apoptotic potential of rhTRAIL-C3 in AML cell lines. HL-60 (A), ML-1 (B), MOLM-13 (C) and OCI-AML-3 (D) were treated with increasing
doses of WT rhTRAIL, rhTRAIL-C3 and D269H/E195R for 24 hrs and induction of apoptosis was determined using annexin V assay. The graphs show the
average percentage of dead cells  S.E.M. determined with flow cytometric analysis of annexin V positivity. Stars (*) indicated significant difference
between connected bar pairs (P 
 0.05, determined with paired t-test).
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Fig. 5. Functionality of DR4 and DR5 in AML cells. HL60 (A), ML-1 (B), MOLM-13 (C) OCI-AML3 (D) and EM-2 cells were treated with WT rhTRAIL, ago-
nistic anti-DR4 and anti-DR5 antibodies for 24 hrs with or without previous crosslinking of the antibodies. Induction of cell death, as a measure of recep-
tor functionality, was measured with 7-aminoactinomycin D staining and flow cytometric analysis. Graphs demonstrate the average percentage of dead
cells (S.E.M.) from three independent experiments.
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Fig. 6. rhTRAIL-C3 activates DR4 more
efficiently than WT rhTRAIL. The kinet-
ics of receptor activation was meas-
ured by determining (A) pro-caspase-8
cleavage (B) IB phosphorylation and
degradation by Western blot analysis,
or (C) apoptosis induction with TMRE
staining. HL-60 cells were treated with
100 ng/ml of WT rhTRAIL or rhTRAIL-
C3 for the times indicated, after which
it was removed from the cells and the
cells washed. To detect induction of
apoptosis after washing the ligands
out, the cells were resuspended in
normal growth medium and incubated
further for 12 hrs in total. The graph
shows induction of apoptosis relative
to maximum apoptosis observed at 
12 hrs (100%). -actin was used in the
Western blot analyses as a protein
loading control.
2226 © 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
sensitive and resistant samples (Fig. 7B, samples 10, 11, 14, 15
and samples 1, 9, respectively). The response of the individual
AML samples ranged from no sensitization (samples 11, 14)
through additive effect (samples 1, 9, 10) to even synergistic
effect (sample 15) to both WT rhTRAIL and rhTRAIL-C3.
Additionally, the combination of rhTRAIL-C3 with BMS-345541
resulted in a stronger cytotoxic effect than WT rhTRAIL (Fig. 7C,
P 0.012 for 5 M BMS-345541 WT rhTRAIL and 5 M BMS-
345541  WT rhTRAIL).
While rhTRAIL-C3 showed high activity on primary AML cells,
it was not toxic to non-transformed, normal cells (Fig. 7D and E).
Human primary dermal fibroblasts as an abundant somatic cell
type were tested for sensitivity to rhTRAIL-C3. Additionally, NHEK
were also tested as keratinocytes have been reported to be sensi-
tive to rhTRAIL-induced apoptosis [36]. In line with the literature,
NHEK cells showed a low level of sensitivity to WT rhTRAIL 
(Fig. 7E). rhTRAIL-C3 did not induce any cell death in fibroblasts
and did not induce significantly more cell death than WT rhTRAIL
in keratinocytes (Fig. 7D and E).
Discussion
TRAIL is a promising anti-cancer agent as it selectively induces
apoptosis in cancer cells while leaving normal cells unharmed.
However, some tumour types, such as AML, are relatively insensi-
tive to TRAIL-induced apoptosis [37–40].
In AML blasts, despite the fact that approximately 50% of
AMLs express at least one death-inducing TRAIL receptor on the
cell surface, TRAIL fails to activate pro-caspase-8, indicating that
inadequate receptor activation by TRAIL contributes to the low
sensitivity [17]. Using agonistic antibodies specific to DR4 or
DR5, we found that similar to some other leukemic cell types,
such as CLL [12], AML cells were more sensitive to DR4 than to
DR5 stimulation. At least half of the AML blasts examined here
expressed DR4 and approximately 75% expressed DR5 (12 and
16 out of 21, respectively) on the cell surface, however, DR5
expression was associated with high DcR2 expression in 11 out of
16 cases (69%). DcR2 has been shown to associate with and
inhibit the function of DR5 [41]. The study by Riccioni et al., using
72 primary AML blasts, demonstrated a strong correlation between
decoy receptor expression and TRAIL sensitivity. As in our study,
this study also identified that most DR5 expressing blasts also
expressed DcR2 (eight of nine samples, 88%) [17]. Overall these
results strongly indicate that the death-inducing TRAIL receptors
are a major point of control of AML TRAIL sensitivity.
To increase the response of AML cells to TRAIL receptor stim-
ulation, we have engineered a TRAIL variant using computational
design. This variant, rhTRAIL-C3 possesses three mutations: a
replacement of glycine to arginine at position 131, a replacement
of asparagine to arginine at position 199 and a lysine to histidine
mutation at position 201. These mutations generated high DR4-
specific agonistic activity. This TRAIL mutant (rhTRAIL-C3) dis-
played significantly stronger pro-apoptotic activity in a range of
AML cell lines. rhTRAIL-C3 activated DR4 more efficiently than WT
rhTRAIL, resulting in a faster and more robust pro-caspase-8 acti-
vation, loss of mitochondrial membrane potential and cell death.
To date there is very little information about the differential reg-
ulation of DR4 and DR5. Rossin and colleagues have reported that
translocation of DR4 to the lipid rafts and induction of apoptosis
required palmitoylation in the membrane proximal, intracellular
region of the receptor, while this event was not required for DR5
[42]. As palmitoylation of N-Ras has been shown to be necessary
for leukogenic transformation [43], there is a possibility that the
same mechanism that activates the Ras pathway also selectively
enhances DR4 functionality.
In addition to mechanisms selectively activating DR4, it is also
possible that other mechanisms selectively inhibit DR5. There is
accumulating evidence that the decoy receptors have differential
effects on DR4 and DR5, with DcR2 preferentially regulating DR5
activity [41, 44]. Furthermore, we have previously shown that the
short isoform of cellular FLICE-like inhibitory protein (c-FLIPs)
preferentially binds to and inhibits apoptotic signalling from the
DR5 DISC and its expression can be controlled by early growth
response-1 (Egr-1) [45]. Finally, a recent report has shown that
similar to our findings on AML, in pancreatic tumours despite the
Table 2 TRAIL receptor cell surface expression in primary AML blasts
DR4 DR5 DcR1 DcR2
1    
2    
3    
4    
5    
6    
7    
8    
9    
10    
11    
12    
13    
14    
15    
16    
17    
18    
19    
20    
21    
: Low level of expression (geometric mean on histogram is
120–200% of isotype control); : medium level of expression 
(geometric mean is 200–300% of isotype control); : high level 
of expression (geometric mean is more than 300% of isotype control).
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expression of both DR4 and DR5, only DR4 is functional [46]. The
study found that protein kinase C activity can selectively inhibit
DR5 function [46].  Protein kinase C (PKC) isoforms regulate
haemopoietic cell growth, differentiation and activation and thus,
PKC-mediated DR5 inhibition may be another explanation why
AML cells rarely have functional DR5 receptors.
Having observed an increased induction of apoptosis in several
AML cell lines, we tested whether rhTRAIL-C3 also has an
enhanced activity in primary AML blasts. rhTRAIL-C3 was indeed
a better activator of apoptosis then rhTRAIL WT in primary AML
blasts. It should be noted that approximately half of the primary
AML samples showed complete resistance to WT rhTRAIL and
many of these samples remained resistant to rhTRAIL-C3, but
rhTRAIL-C3 showed enhanced activity in all samples which had
some sensitivity to WT rhTRAIL.
It has to be noted that a significant proportion of AML cells do
not express DR4 on the cell surface. It means that if rhTRAIL-C3
enters therapy, it should be used either in combination with drugs
that induce DR4 expression in AML cells, or identify the patient pop-
ulation where the blast cells express DR4. Riccioni and colleagues
have reported a comprehensive study of TRAIL receptor expression
in primary AML [17]. Similarly to our results, they show that DR4
expression associates with AMLs displaying monocytic or to a
lesser extent, myelomonocytic phenotype. Thus, the M5a/M5b FAB
classified AML types are potential targets for the rhTRAIL-C3 vari-
ant. Additionally, DR4/DR5 typing of blast samples using flow
cytometry could be utilized in the clinic to identify patient suitability.
Histone deacetylase inhibitors, such as valproic acid and
LAQ824 as well as irradiation have been reported to induce DR4
expression in erythroleukaemias and in certain AMLs and sensitize
Table 3 Clinical parameters for patient samples studied for TRAIL receptor
Sample 
number
Sex Age
Primary/
secondary?
WBC Karyotype
Cytogenetic
risk group
FAB
subtype
Treatment
intensity
Clinical 
Outcome
1 M 52 Primary 21.5 45,X,Y,t(8;21)(q22;q22)[10] Favourable M4 Intensive CR
2 M 51 Primary 91.8 50,XY,6,8,13,inv(16)(p13q22),22[10] Favourable M4e Intensive CR
3 M 33 Primary 71 46,XY,inv(16)(p13q22)[10] Favourable M4 Intensive CR
4 M 77 Primary 8.8 Unknown Non-intensive
Resistant
disease
5 M 42 Secondary 107.4 46,XY,inv(16)(p13q22)[10] Favourable M4e Intensive CR
6 F 41 Primary 47.1 46,XX[20] Intermediate M1 Intensive CR
7 M 81 Primary 40 46,XY[20] Intermediate Unknown Non-intensive
Induction
death
8 F 69 Primary 73.5 45,XX,7[13] Adverse M4 Non-intensive
Resistant
disease
9 M 85 Primary 45.8 46,XY[20] Intermediate Unknwon Non-intensive CR
10 F 80 Secondary 89.9 Unknown Non-intensive
Induction
death
11 M 77 Primary 130 46,XY[20] Intermediate M1 Non-intensive CR
12 M 56 Primary 31.1 46,XY,t(6;9)(p23;q34)[9]/46,XY[1] Intermediate M1 Intensive CR
13 M 60 Primary 21 46,XY,t(13;19)(q14;p11)[10] Intermediate M4 Intensive CR
15 F 72 Secondary 104 46,XX[20] Intermediate M4 Non-intensive
Resistant
disease
16 M 48 Primary 171.5 46,XY[20] FLT3ITD positive Intermediate M1 Intensive
Resistant
disease
17 M 62 Primary 69.5 46,XY,t(9;11)(p21;q23)[10] — Intermediate M5a Intensive .
18 M 68 Secondary 20.4 45,XY,inv(3)(q21q26),7[10] Adverse Other Intensive .
19 M 69 Primary 35.3 47,XY,21[13]/50,idem,8,9,14[3]/46,XY[4] Adverse M4 Intensive CR
20 F 36 Primary 148.9 46,XX[20] Intermediate M1 Intensive CR
21 M 85 Secondary 69.2 . RAEB Non-intensive
Induction
death
M: male; F: female; WBC: white blood cell count; CR: complete remission; FAB: French–American–British classification.
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Fig. 7. rhTRAIL-C3 is a more potent inducer of AML blast apoptosis than WT rhTRAIL. Primary AML blasts were treated with 250 ng/ml of WT rhTRAIL
(WT) or rhTRAIL-C3 (C3) as single agents (A), or in combination with 5 M BMS-345541 (BMS) for 24 hrs (B). Induction of apoptosis was measured
with annexin V staining and expressed as percentage apoptosis induced in the live population. (C) shows the averaged effect of WT rhTRAIL, rhTRAIL-
C3 or their combination with 5 M BMS-345541 in the six samples shown in (B). The * denotes significant differences, P 
 0.05 determined with paired
t-test. (D, E) rhTRAIL-C3 does not show increased toxicity in non-transformed cells. (D) Primary human dermal fibroblasts and (E) primary normal human
epidermal keratinocytes were treated with the indicated doses of WT rhTRAIL or rhTRAIL-C3 for 24 hrs. Induction of cell death was quantified with annexin
V assay and flow cytometry. The graphs show the average  S.E.M. values from at least three independent repeats. There was no significant difference
between WT rhTRAIL- and rhTRAIL-C3-induced apoptosis at any of the concentrations tested (P  0.05 with paired Student’s t-test).
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these leukaemias to TRAIL [47, 48]. Combination of such thera-
peutics with rhTRAIL-C3 could increase the spread of leukaemias
where rhTRAIL-C3 could be efficaceous.
Thus, rhTRAIL-C3 may only work as a single agent only in
cases where resistance mechanisms are not present downstream
of the TRAIL receptor (e.g. c-FLIP expression, low caspase-8 lev-
els, or overexpression of Mcl-1 and XIAP). There is a strong
rationale to combine receptor-selective TRAIL variants with agents
that can target such mechanisms [33, 49, 50]. As an example,
here we show that combination of WT rhTRAIL and rhTRAIL-C3
with the IKK inhibitor BMS-345541 resulted in increased sensitiv-
ity to WT rhTRAIL. However, similar to the single agent studies,
the combination of rhTRAIL-C3 with BMS-345541 was more effi-
cient than WT rhTRAIL. It exemplifies that combination of this
TRAIL variant with chemotherapeutics or other targeted agents
can kill AML with high efficacy. This could improve patient out-
come and reduce the toxic side effects typical of the currently
applied drug treatments by enabling the use of lower drug doses.
In conclusion, in AML cell lines TRAIL mediates apoptosis pri-
marily via DR4. rhTRAIL-C3 is a novel and more potent TRAIL
molecule which has superior DR4-activating potential compared
to WT rhTRAIL. The activity of this variant could be further
enhanced by inhibiting the DR4-mediated activation of NF-B
indicating that TRAIL variants with strong DR4-specific agonistic
activity may represent a novel approach for treating AML either as
a single agent, or in combination therapy.
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Fig. S1 DR4-selectivity and pro-apoptotic potential of
N199R/K201H and G131R/D218H TRAIL mutants. (A) DR4-
responsive ML-1 acute myelogenous leukaemia cells (B) and EM-
2 chronic myelogenous leukaemia cells (C) as well as DR5-
responding A2780 ovarian carcinoma cells (C) were treated with
increasing doses of WT rhTRAIL, rhTRAIL-C3, G131R/D218H and
N199R/K201H for 24 hrs. Induction of apoptosis was determined
using annexin V assay and flow cytometric analysis. The graphs
presented demonstrate the percentage of dead cells  S.E.M. as
determined from three independent experiments.
Fig. S2 Gel filtration elution profile of WT rhTRAIL (A) and
rhTRAIL-C3 (B) from Hiload Superdex 75 16/60 column.
Fig. S3 Time versus response SPR sensorgrams. Receptor bind-
ing of WT rhTRAIL (A, C) and rhTRAIL-C3 (B, D) towards DR4-Ig
(A, B) and DR5-Ig (C, D). Receptor chimeras were coated at a level
of ~600–1000 RU. Purified WT rhTRAIL and rhTRAIL-C3 were
injected in 3-fold at concentrations ranging from 250 to 2 nM at
70 l/min. flow rate using HBS-P (Biacore) as running and sam-
ple buffer. Binding of ligands to the receptors was monitored in
real time at 37C.
Fig. S4 Receptor binding of WT rhTRAIL and rhTRAIL-C3 variant
determined by SPR and competitive ELISA. Pre-steady state
receptor binding curves of WT rhTRAIL and rhTRAIL-C3 to DR4-
Ig (A), or to DR5-Ig (B) as determined by SPR. The response at
each concentration was recorded 30 sec. after the end of the injec-
tions. Competitive ELISA assay of WT rhTRAIL and rhTRAIL-C3
for TRAIL receptors using immobilized DR4-Ig receptor and solu-
ble DR4-Ig as competitor (C), soluble DR5-Ig as competitor (D),
soluble DcR1-Ig as competitor (E) or soluble DcR2-Ig as competi-
tor (F). Binding was calculated relative to the value measured in
the presence of 0 ng/well of soluble receptor.
Fig. S5 Inhibition of NF-B activity with the IKK inhibitor BMS-
345541 (Calbiochem) enhanced the biological activity of both WT
rhTRAIL and rhTRAIL-C3. HL-60 cells were treated with 100 ng/ml
(A) or 10 ng/ml (B) of WT rhTRAIL or rhTRAIL-C3 in the presence
or absence of the indicated concentrations of BMS-345541 for 
12 hrs. Induction of cell death was determined by measuring the
loss of mitochondrial membrane potential with TMRE. The graphs
show average percentage of cells with low mitochondrial mem-
brane potential (	m).
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